-+ 0.00%
-+ 0.00%
-+ 0.00%

ATEA PHARMACEUTICALS ANNOUNCES DOSING OF FIRST PATIENT IN C-BEYOND, PHASE 3 STUDY EVALUATING REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS

Reuters·04/09/2025 11:00:01

Please log in to view news